NCT00059787View on ClinicalTrials.gov

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Brenner TumorFallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
DRUG

paclitaxel

Given IV

DRUG

carboplatin

Given IV

DRUG

erlotinib

Given PO

Trial Locations (1)

10467-2490

Montefiore Medical Center, The Bronx

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00059787 - Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | Biotech Hunter | Biotech Hunter